Printer Friendly

ARCTURUS PHARMACEUTICAL CORPORATION NAMES RICHARD J. SHARPE, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER

 WOBURN, Mass., Nov. 11 /PRNewswire/ -- Arcturus Pharmaceutical Corporation announced today that the company has named Richard J. Sharpe, M.D., president and chief executive officer. Dr. Sharpe, a co-founder of the company and a member of the board of directors, was previously executive vice president.
 "Dr. Sharpe has been a key contributor to the growth of the company and the rapid entry of our dermatological products into clinical development," said Craig Jones, chairman of the board of Arcturus. "His leadership will be important as these products advance and as we expand our pipeline of innovative dermatological products." Arcturus recently began several clinical trials under three INDs. The trials include a Phase I clinical study with a novel topical formulation of the antihistamine dexchlorpheniramine for the treatment of pruritis (itch), and two pilot clinical studies of an anti-inflammatory agent.
 Prior to joining Arcturus, Sharpe was a clinical instructor in dermatology at Harvard Medical School and he held a research position at Repligen Corporation. A board-certified clinical dermatologist, Sharpe received his M.D. degree from the University of Connecticut and obtained his dermatology training at Harvard Medical School. His research on topical immunosuppressants is one of the key technologies on which the company was founded. Sharpe succeeds Rex Bright, who will serve as a consultant to the company.
 Arcturus was established in 1991 to use advances in skin biology to develop and commercialize clinically superior products for dermatologic disorders.
 The company's proprietary technology includes a series of immunosuppressant compounds and prodrugs as well as drug delivery technology that enhances penetration of therapeutic compounds into the skin. Products in development currently include topical therapies for psoriasis, other immunologically mediated disorders such as atopic dermatitis, and a potentially fatal form of skin cancer.
 -0- 11/11/93
 /CONTACT: Richard Sharpe, M.D., president and CEO of Arcturus Pharmaceutical, 617-938-1686; or Robert Gottlieb, senior vice president of Feinstein Partners, 617-577-8110/


CO: Arcturus Pharmaceutical Corp. ST: Massachusetts IN: MTC SU: PER

DJ -- NE004 -- 3095 11/11/93 09:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 11, 1993
Words:334
Previous Article:BOSTON TECHNOLOGY APPOINTS RICHARD SNELLING TO THE BOARD OF DIRECTORS
Next Article:REHABCLINICS, INC. REPORTS RECORD REVENUES AND EARNINGS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters